We are excited to announce the publication of a groundbreaking study by our team of researchers in the preprint server medRxiv. The study, titled "Multiplexed RNA-FISH-guided Laser Capture Microdissection RNA Sequencing Improves Breast Cancer Molecular Subtyping, Prognostic Classification, and Predicts Response to Antibody Drug Conjugates", presents a novel approach that significantly advances breast cancer diagnostics and treatment prediction.

The key findings of this study include:

1. Improved Breast Cancer Molecular Subtyping: By utilizing multiplexed RNA-FISH-guided laser capture microdissection and RNA sequencing, the researchers were able to achieve more accurate and detailed molecular subtyping of breast cancer samples compared to conventional methods.

2. Enhanced Prognostic Classification: The new technique demonstrated superior performance in classifying breast cancer patients into clinically relevant prognostic groups, enabling more personalized treatment strategies.

3. Prediction of Response to Antibody Drug Conjugates: The study showed that the molecular profiles obtained through this approach can accurately predict a patient's likelihood of responding to antibody drug conjugate therapies, which are emerging as a promising treatment option for breast cancer.

"This study represents a major step forward in the field of breast cancer diagnostics and treatment selection," said Dr. Pavol Čekan, CEO of MultiplexDX. "By combining advanced RNA-based technologies, we are able to provide clinicians with more comprehensive and reliable information to guide their decision-making and improve patient outcomes."

The publication of this research in a prestigious preprint server highlights the innovative nature of our work and the potential impact it can have on the lives of breast cancer patients. We are committed to further advancing this technology and making it accessible to healthcare providers worldwide. For more information about this study and our ongoing research initiatives, please visit our website www.multiplexdx.com or contact us at info@multiplexdx.com.

Have a look at the preprint HERE https://www.medrxiv.org/content/10.1101/2023.12.05.23299341v1